The ATN [β amyloid, tau, neurodegeneration] framework has been introduced to define the underlying neurodegenerative alterations of the disorder and tends to displace the traditional clinical diagnostic approach; β amyloid deposition, tau aggregation, and neurodegenerative changes characteristic of AD not only improve its challenging differential diagnosis but also facilitate early identification—even in a preclinical stage—allowing timely interventions and serving research purposes [50,51,52]. Here, MAPT is linked to Alzheimer disease.